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Abstract
Introduction: Childhood obesity has been associated with the development of insulin resistance, potentially leading to several metabolic 
disorders. Osteocalcin has been reported to contribute to the regulation of glucose tolerance and insulin sensitivity. 
The purpose of this study was to examine the relationship between serum osteocalcin and metabolic risk factors in obese children and 
adolescents. 
Material and methods: Age, gender, pubertal stage, adiposity markers (standard deviation score of body mass index: BMI-SDS, percentage 
of body fat, waist circumference), blood pressure, serum osteocalcin (OC), fasting plasma glucose and insulin, glycated haemoglobin level 
(HbA1c), insulin resistance estimated by homeostasis model assessment (HOMA-IR), lipid profile, C-reactive protein (CRP), fibrinogen 
(FB), white blood cell count (WBC) and 25-hydroxyvitamin D (25-OH-D) were evaluated in 142 obese children and adolescents. Stepwise 
multiple regression analysis was used to determine the relationship between serum osteocalcin and metabolic risk parameters. 
Results: Mean serum osteocalcin level was 72.0 ± 20.5 μg/L (range: 16.8–181.5 μg/L). After adjustment for multiple potential confound-
ers, serum osteocalcin concentration was inversely associated with adiposity markers as well as HOMA-IR, HbA1c, triglycerides, CRP, FB 
and positively with 25-OH-D and HDL-cholesterol. In stepwise multiple linear regression analysis adjusted for age, gender and pubertal 
stage, osteocalcin was significantly negatively related to HOMA-IR, triglycerides and waist circumference. 
Conclusions: Serum osteocalcin concentration is associated with blood markers of dysmetabolic phenotype and measures of adiposity, 
suggesting that osteocalcin is important not only for bones but also for glucose and fat metabolism as early as during childhood. 
(Endokrynol Pol 2013; 64 (5): 346–352)
Key words: adolescents, children, metabolic disorders, obesity, osteocalcin
Streszczenie
Wstęp: Otyłość u dzieci wiąże się z rozwojem insulinooporności i ryzykiem wielu zaburzeń metabolicznych. Osteokalcyna odgrywa rolę 
w kształtowaniu tolerancji glukozy oraz wrażliwości na insulinę. Celem pracy było zbadanie zależności pomiędzy stężeniem osteokalcyny 
w surowicy a czynnikami ryzyka zaburzeń metabolicznych u dzieci i młodzieży.
Materiał i metody: Wśród czynników ryzyka zaburzeń metabolicznych, których związek ze stężeniem osteokalcyny w surowicy analizo-
wano w modelu wielokrotnej regresji krokowej w grupie 142 otyłych dzieci i młodzieży, znalazły się: płeć, stopień dojrzałości płciowej, 
markery otłuszczenia (odchylenie standardowe wskaźnika masy ciała: BMI-SDS, odsetek tkanki tłuszczowej, obwód talii), ciśnienie tęt-
nicze krwi, stężęnie osteokalcyny w surowicy, stężenie glukozy i insuliny na czczo, zawartość hemoglobiny glikowanej (HbA1c), stopień 
oporności na insulinę oceniany na podstawie modelu homeostatycznego (HOMA-IR), profil lipidowy, stężenie białka C-reaktywnego 
(CRP) i fibrynogenu (FB), liczba krwinek białych oraz stężenie 25-hydroksywitaminy D (25-OH-D).
Wyniki: Średnie stężenie osteokalcyny w surowicy wyniósł 72,0 ± 20,5 μg/l (zakres: 16,8–181,5 μg/L). Po uwzględnieniu poprawki na 
potencjalne czynniki zakłócające, stężenie osteokalcyny okazało się być odwrotnie skorelowane z poziomem markerów otłuszczenia, 
a także z HOMA-IR, HbA1c, stężeniem triglicerydów, CRP i FB; stwierdzono też dodatnią korelację ze stężeniem 25-OH-D i HDL. W mo-
delu wielokrotnej regresji krokowej, uwzględniającym poprawkę na wiek, płeć oraz stopień dojrzałości płciowej, stężenie osteokalcyny 
okazało się być odwrotnie skorelowane z HOMA-IR, stężeniem triglicerydów i obwodem talii.
Wnioski: Stężenie osteokalcyny w surowicy wykazuje związek z wykładnikami zaburzeń metabolicznych oraz miernikami otłuszcze-
nia; obok udziału w metabolizmie tkanki kostnej, osteokalcyna wydaje się więc odgrywać istotną rolę w przemianach glukozy i lipidów 
u dzieci. (Endokrynol Pol 2013; 64 (5): 346–352)
Słowa kluczowe: osteokalcyna, zaburzenia metaboliczne, otyłość, dzieci, młodzież
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Childhood obesity is known to be an important risk fac-
tor for the development of insulin resistance potentially 
leading to several metabolic conditions such as impaired 
glucose tolerance, type 2 diabetes, atherosclerosis and 
hypertension [1]. Abnormalities of bone metabolism are 
quite often found in patients with obesity and glucose dis-
turbances, especially in diabetic subjects. Even overweight 
children are prone to fractures, although their bone min-
eral density may not be particularly low [2]. Over the past 
decade, it has been shown that bone-associated proteins, 
such as osteocalcin, osteopontin, and osteoprotegerin are 
found in atherosclerotic arteries, suggesting that these 
molecules could be associated with vascular diseases [3]. 
More recently, experimental studies have confirmed that 
the skeleton is not only an organ of locomotion but may 
act as an endocrine organ which participates in energy me-
tabolism and glucose homeostasis through secretion of an 
osteoblast-derived protein – osteocalcin [4, 5]. Osteocalcin, 
a known marker of bone formation, decreases visceral fat 
mass, increases energy expenditure, and promotes insulin 
sensitivity by increasing the number of pancreatic β-cells 
and insulin secretion. Lee et al. [4] showed that mice lack-
ing osteocalcin have an increased amount of visceral fat 
and display glucose intolerance, insulin resistance and 
increased serum triglyceride levels compared to wild-
type mice. Moreover, injections of osteocalcin improve 
glucose metabolism and prevent the development of type 
2 diabetes in mice [6]. Although these findings confirm the 
hypothesis of a regulatory hormonal loop between bone 
and adipose tissue, little is known about whether serum 
osteocalcin concentration is associated with fat mass, glu-
cose, insulin, and atherosclerosis risk factors in children. 
In this study, we investigate the relationship between 
serum osteocalcin level and the parameters of adiposity 
as well as blood markers characteristic of the dysmetabolic 
phenotype in obese children and adolescents.
Material and methods
Study group
The participants in this study were 142 obese subjects 
(68 boys and 74 girls), aged 6 – 18 years, attending the 
Outpatients Clinic for Children with Metabolic Disor-
ders. Obesity was recognised on the basis of a Body 
Mass Index (BMI) > 97th percentile for age and sex on 
the BMI percentile charts for the Polish population 
of children and adolescents [7]. Children with acute 
or chronic infections, as well as children with signifi-
cant medical conditions such as genetic syndromes, 
cancers, autoimmunologic diseases, hepatic or renal 
dysfunction, hormonal abnormalities or diabetes, were 
excluded. No patients were taking medications such 
as corticosteroids, vitamin D or calcium, nor were any 
drinking alcohol or smoking cigarettes. 
The protocol of this study was approved by the Ethi-
cal Committee of the Pomeranian Medical University. 
Written parental consent and patients’ assent were 
obtained before entering the study.
Anthropometric and clinical measurements
All anthropometric measurements (height, weight and 
waist circumference) were carried out by the same 
trained staff, with the patients wearing only under-
wear. Height was measured using a wall-mounted 
Harpender’s stadiometer, and weight was measured 
on an electronic scale. Body mass index (BMI) was cal-
culated by dividing weight (in kg) by height in square 
metres (kg/m2). Since BMI changes with age during 
childhood, the BMI-standard deviation score (BMI-
SDS) was also calculated [7]. The waist circumference 
was measured as a minimal abdominal circumference, 
between the xiphoid process and iliac crest. Because the 
waist circumference increases with age, it was expressed 
as a standard deviation score (waist-SDS) [8]. Percentage 
body fat (% FAT) and fat mass (in kg) were measured 
in the fasted state using the bioimpedance methods 
and a fixed-frequency (50 kHz) bioimpedance analysis 
analyser (Bioelectrical Impedance Analyzer Tanita 131, 
Japan) with an applied current of 0.8 mA.
Physical examination was performed to check the 
general health status as well as determine the pubertal 
status, according to the criteria of Tanner. In girls, breast 
stage was used if there was a discrepancy between 
breast and pubic hair development, whereas in boys, 
pubic hair was used if there was a discrepancy between 
genitalia and pubic hair staging.
Ambulatory blood pressure monitoring (ABPM) 
was performed using a Mobil-O-Graph device, which 
uses the oscillometric method. Systolic (SBP) and 
diastolic blood pressure (DBP) were measured half-
hourly between 7 a.m. and 11 p.m., and hourly between 
11 p.m. and 7 a.m.
For the purposes of serum vitamin D analysis, we 
defined seasons by months: winter (December-May) 
and summer (June-November). 
Blood analyses
All measurements were made in the morning after a 
12-h overnight fast. Serum osteocalcin was measured 
by immunoradiometric assay (OSTEO-RIACT, IBA CIS 
BIO, F) with intra-a and inter-assay CVs of 4.0 and 6.0%, 
respectively. The assay detects both uncarboxylated and 
carboxylated osteocalcin. Serum 25-OH-D level was meas-
ured using Nichols radioimmunoassay (Nichols Institute, 
San Clemente, CA, USA). Glucose was measured with the 
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pus, Japan). Free insulin concentration was determined by 
a commercial radioimmunoanalysis - RIA (Pharmacia RIA 
kit). Glycated haemoglobin (HbA1c) level was measured 
by the immunoturbimetric method (Olympus, Japan). 
Determination of serum concentration of C-reactive pro-
tein (CRP) was performed using the high-sensitivity assay 
based on the immunoturbidimetric method (Olympus). 
Total cholesterol (T-chol), HDL cholesterol (HDL-chol) 
and triacylglycerol (triglycerides-TG) were measured 
by automated enzymatic procedures (Olympus). LDL 
cholesterol (LDL-chol) was determined after separating 
LDL fraction of cholesterol from fresh serum by sequential 
ultracentrifugation, using an Olympus commercial kit. 
White blood cell count was measured by a commercial 
kit (Olympus).
Insulin resistance was estimated using the homeo-
static model assessment index (HOMA-IR) calculated 
according to the following formula: HOMA-IR = fasting 
blood glucose (mmol/L) x fasting insulin (mU/L)/22.5 [9].
Statistical analysis
Statistical analysis was performed using the STATA 11 
software package. Conformity to a normal distribution 
was tested by the Kołmogorov-Smirnov test. For quan-
titative variables that were normally distributed, results 
are expressed as mean value ± standard deviation (SD).
Statistically significant differences were tested for 
quantitative items by the Student’s t-test, and for quali-
tative items by the χ2 test. The cohort of patients was 
also divided into quartiles by osteocalcin concentration. 
Since the number of patients in the 2nd and 3rd quartiles 
was relatively small (19 and 20 subjects, respectively), 
they were analysed and presented collectively. For 
comparisons among the three groups, one-way analysis 
of variance for independent samples was used. Associa-
tion between serum OC levels and adiposity markers 
(BMI-SDS, percentage of body fat, waist-SDS) as well 
as biochemical parameters were examined with Pear-
son’s correlation. A stepwise multiple linear regression 
analysis for serum osteocalcin (as an independent 
variable) and other clinical and analytical markers of 
metabolic risk was performed. Statistical significance 
for all analyses was set at p < 0.05.
Results
The general characteristics of children participating in 
this study are presented in Table I.
Serum osteocalcin level was significantly higher 
in boys than in girls (79.1 ± 27.6 v. 65.5 ± 32.2 ng/mL; 
p = 0.044; data not shown). Pubertal stage and season 
were not associated with serum OC (P = 0.074 and 
p = 0.725, respectively).
When we divided the cohort into quartiles by serum 
osteocalcin concentration (with the 2nd and 3rd quartile 
analysed together), anthropometric and biochemical 
parameters varied inversely with OC quartile with the 
exception of age and serum 25-OH-D level (Table II). 
In the correlation analysis, performed in the whole 
group, circulating osteocalcin was inversely associated 
Table I. Clinical features and metabolic parameters in study participants
Tabela I. Charakterystyki kliniczne i metaboliczne uczestników badania
Demographic and clinical Glucose/insulin metabolism
Age (years) 13.8 ± 2.6 Glucose [mmol/L] 5.1 ± 0.4
Sex [male/female] 68 / 74 Insulin [mU/L] 20.4 ± 10.7
Tanner stage [1–5] 19, 23, 25, 11, 63 HOMA-IR 4.8 ± 2.5
Weight [kg] 80.1 ± 20.3 HbA1c (%) 5.5 ± 0.3
BMI [kg/m2] 30.1 ± 4.4 Lipid profile
BMI-SDS 3.8 ± 1.4 T-chol [mg/dL] 170.3 ± 26.8
% body fat 35.0 ± 4.9 HDL-chol [mg/dL] 46.9 ± 10.4
Fat mass [kg] 28.2 ± 9.5 LDL-chol [mg/dL] 102.9 ± 26.0
Waist [cm] 101.8 ± 13.6 TG [mg/dL] 121.9 ± 37.9
Waist-SDS 4.3 ± 1.6 Inflammatory markers
SBP [mm Hg] 124.4 ± 11.2 CRP [mg/L] 1.3 ± 0.5
DBP [mm Hg] 80.4 ± 10.1 FB [mg/dL] 315.9 ± 58.5
WBC [G/L] 7.0 ± 1.6
Bone markers
Osteocalcin [ng/mL] 72.0 ± 40.5
25-OH-D [ng/mL] 12.4 ± 6.8
Data is presented as mean ± SD
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with markers of the dysmetabolic phenotype, BMI-SDS 
(r = 0.23; p < 0.01), % FAT (r = 0.22; p < 0.01), fat mass 
(r = 0.29; p < 0.001), waist-SDS (r = 0.36; p < 0.001), 
CRP (r = 0.38; p < 0.001), WBC (r = 0.25; p < 0.01), 
fasting insulin (r = 0.45; p < 0.001), HOMA-IR (r = 0.43; 
p < 0.001), LDL-chol (r = 0.27; p < 0.01), triglicerydes 
(r = 0.42; p < 0.001), FB (r = 0.52; p < 0.001), HbA1c 
(r = 0.45; p < 0.001), SBP (r = 0.36; p < 0.001), DBP 
(r = 0.34; p < 0.001) after adjustment for age, sex, pu-
bertal stage and season. Positive correlations between 
serum osteocalcin and HDL-chol (r = 0.37; p < 0.001) 
and 25-OH-D (r = 0.38; p < 0.001) were also found.
Stepwise multiple regression analysis for OC and 
the remaining analysed variables showed a negative 
correlation with insulin resistance index (r = 0.33; 
p < 0.001), triglycerides (r = 0.22; p < 0.01) and waist-SDS 
(r = 0.18; p < 0.05). Neither CRP nor 25-OH-D correlated 
with serum osteocalcin level by this stepwise regression 
model (Table III).
Discussion
In this study performed in obese children and adoles-
cents, we found that serum osteocalcin was inversely 
associated with blood and adiposity markers of the 
dysmetabolic phenotype, including insulin resistance, 
abnormal lipid profile, systemic inflammation and 
body fatness. This was confirmed by differences in 
Table II. Characteristics of studied patients divided by osteocalcin quartile
Tabela II. Charakterystyki badanych pacjentów w zależności od tercyla stężenia osteokalcyny
Osteocalcin quartile [ng/mL]
≤ 34.6
1st quartile  
(n = 44)
34.7–97.0
2nd and 3rd quartile  
(n = 39, i.e. 19 + 20)
≥ 97.1




Age (years) 15.5 ± 1.9 13.0 ± 2.7 13.6 ± 2.4 < 0.001
Weight [kg] 85.8 ± 20.7 75.7 ± 21.6 72.9 ± 15.1 0.002
BMI [kg/m2] 34.3 ± 5.4 29.5 ± 4.4 28.9 ± 1.2 0.027
BMI-SDS 4.8 ± 1.4 3.8 ± 1.4 3.2 ± 1.2 0.050
% body fat 45.7 ± 5.9 36.9 ± 4.6 32.4 ± 4.8 0.001
Fat mass [kg] 30.5 ± 10.7 29.1 ± 8.4 26.5 ± 9.4 0.019
Waist [cm] 107.4 ± 14.2 99.8 ± 13.2 95.4 ± 12.5 0.002
Waist-SDS 5.0 ± 1.7 4.2 ± 1.3 3.7 ± 1.7 < 0.001
SBP [mm Hg] 130.4 ± 9.8 122.2 ± 10.9 115.6 ± 11.3 < 0.001
DBP [mm Hg] 85.3 ± 10.9 79.3 ± 8.8 76.6 ± 10.2 < 0.001
Glucose/insulin metabolism
Glucose [mmol/L] 5.2 ± 0.4 5.1 ± 0.4 5.0 ± 0.3 0.443
Insulin [mU/L] 26.6 ± 12.3 19.5 ± 9.8 15.9 ± 7.7 < 0.001
HOMA-IR 6.1 ± 2.8 4.5 ± 2.0 3.5 ± 1.7 < 0.001
HbA1c (%) 5.6 ± 0.3 5.5 ± 0.3 5.2 ± 0.3 < 0.001
Lipid profile
T-chol [mg/dL] 175.1 ± 32.6 169.2 ± 26.1 167.7 ± 21.3 0.522
HDL-chol [mg/dL] 41.8 ± 9.9 47.6 ± 9.7 50.7 ± 10.7 < 0.001
LDL-chol [mg/dL] 111.9 ± 29.7 102.1 ± 24.7 95.3 ± 22.2 0.003
TG [mg/dL] 153.9 ± 47.8 117.5 ± 52.9 98.3 ± 41.1 0.001
Inflammatory markers
CRP [mg/L] 1.7 ± 0.8 1.3 ± 0.4 1.0 ± 0.5 < 0.001
FB [mg/dL] 358.3 ± 52.7 308.3 ± 49.1 288.4 ± 59.0 < 0.001
WBC [G/L] 7.5 ± 1.7 7.0 ± 1.5 6.7 ± 1.5 0.027
Bone markers
25-OH-D [ng/mL] 9.1 ± 3.8 12.6 ± 6.1 16.2 ± 7.3 < 0.001
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OC concentrations according to adiposity status and 
metabolic risk profile. Serum osteocalcin decreases with 
increasing percent of body fat and waist circumference 
as well as insulin concentration, HOMA-IR, HbA1c and 
inflammatory markers. Moreover, low serum 25-OH-
D concentration, a known marker for dysmetabolic 
phenotype, was also correlated with low circulating 
OC. These findings suggest that osteocalcin acts as 
a negative regulator of fat mass and has favourable ef-
fects on fat and glucose metabolism in obese children. 
A reciprocal interaction between bone and energy 
metabolism has long been suspected, based on clinical 
observations that obesity is inversely associated with 
osteoporosis. It is now known from experimental stud-
ies that there is an endocrine regulation of glucose and 
fat metabolism by the skeleton, via osteoblast-secretory 
product – osteocalcin [4, 5, 10]. Recent human studies 
have also shown a relationship between OC and fat and 
carbohydrate metabolism [11, 12]. Osteocalcin has been 
reported to be decreased in patients with type 2 diabetes 
[13, 14], negatively correlated with fasting plasma glucose, 
HbA1c, insulin resistance, C-reactive protein and BMI [15, 
16], and increased with improved glycaemic control [12, 
17]. There is increasing evidence that serum osteocalcin 
level is associated with the presence of metabolic syn-
drome [18, 19]. These are consistent with the results of our 
study in which significant correlations between circulating 
osteocalcin and several parameters of dysmetabolic phe-
notype, such as abdominal obesity, insulin resistance, and 
serum triglycerides, were also found. It is commonly ac-
cepted that the presence of metabolic syndrome increases 
the risk of mortality from cardiovascular diseases (CVD). 
Therefore, reduced level of osteocalcin might modulate 
cardiovascular risk. The recent study by Yeap et al. [20] 
showed that total OC predicts all-cause and CVD-related 
mortality in older men. However, this relationship was 
U-shaped which suggests that both men with low and 
those with high osteocalcin levels have increased risk of 
CVD-induced mortality.
Data concerning serum osteocalcin in children is 
limited and results are often controversial [21–24]. Se-
rum osteocalcin levels have been found to be lower in 
obese than in non-obese children [22] and correlated 
inversely with both BMI and body fat [23, 25]. However, 
the correlation between OC and body composition was 
most significant for absolute fat mass compared to other 
indices of adiposity (% of body fat, BMI, or BMI-SDS) 
[25]. These results suggest that circulating osteocalcin is 
more influenced by absolute fat mass than by propor-
tion of body fat. In our study, the percentage of body 
fat and fat mass was determined by the bioimpedance 
method, using novel Tanita body-fat analyser. Methods 
of body fat determination are considered either as ‘ref-
erence’ or ‘prediction’ techniques. Reference methods, 
such as body density, total body water, or dual-energy 
X-ray absorptiometry (DXA), determine certain physical 
properties of the body, whereas prediction methods, e.g. 
skinfold thicknesses and bioelectrical impedance, use 
regression analysis to estimate the outcome of one or 
more reference techniques; traditionally, these are total 
body water measurements for bioelectrical impedance 
and body density for skinfold thicknesses. Jebb et al. 
[26] demonstrated that the practical simplicity of the 
bioimpedance method in Tanita analyser was not as-
sociated with a clinically significant decrease in perfor-
mance compared to the reference methods. Regarding 
body composition, a study of prepubertal overweight 
children with prediabetes showed that greater levels of 
central fat rather than total adiposity may be deleteri-
ous for the developing bone [24]. This is in concord-
ance with the results of our study, in which serum OC 
correlated with all adiposity indices, but in stepwise 
multiple regression analysis only waist circumference 
was an independent predictor of serum osteocalcin.
Contradicting the previous observation [22], Roche-
fort et al. [23] did not find any differences in serum 
osteocalcin levels in obese children compared to non-
obese controls. A possible explanation for the inconsist-
ent data linking childhood adiposity and circulating 
osteocalcin can be attributed to the studied group, 
since the relationships between markers of calcium 
metabolism and body composition showed racial and 
ethnic differences [25].
In concordance with our results, Reinher and Roth 
[22] reported a negative association between serum 
OC concentration and HOMA-IR, a measure of insulin 
resistance. Other paediatric studies have also shown 
a significant association between circulating osteocalcin 
concentrations and blood markers of the dysmeta-
bolic phenotype in obese children [23, 25], although 
Boucher-Berry et al. [25] found such an association only 
Table III. Stepwise multiple regression analysis between 
serum osteocalcin and different metabolic risk parameters 
in obese children*
Tabela III. Model wielokrotnej regresji krokowej oceniający 
związek pomiędzy stężeniem osteokalcyny w surowicy a 
różnymi czynnikami ryzyka zaburzeń metabolicznych u 
dzieci z otyłością*
Variable r p value R for stepwise  
regression model
0.63
HOMA-IR –0.33 < 0.001
TG –0.22 0.003
Waist-SDS –0.18 0.033
*After adjustment for age, gender and pubertal stage
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in whites. It is possible that other variables related to 
adiposity, such as pubertal status, which may affect OC, 
were not assessed in the latter study.
Furthermore, our study revealed a gender-related 
difference in serum osteocalcin level in obese children 
and adolescents. Studied boys had significantly higher 
serum OC concentrations compared to girls. Such a 
gender-related difference constitutes an interesting 
finding; this phenomenon was previously documented 
in studies of healthy children and adolescents [27, 28]. 
Adjustment for BMI-SDS and fat mass (data not shown) 
suggests that the gender-related difference in serum OC 
concentration observed in our group was independent 
of body size. It may rather result from gender-related 
differences in serum 25-OH-D levels that were also 
observed in our study (data not shown) or from dif-
ferences in growth rates during puberty. Fares et al. 
[28] showed that serum OC in girls is maximal at mid-
puberty (i.e. when the pubertal growth spurt occurs) 
and decreases towards the adult level by Tanner stage 
V. In contrast, circulating OC in boys increases during 
early pubertal stages but does not decrease by Tanner 
stage V, and persists longer than in girls. As most of 
our subjects were pubertal, the effects of gender can 
be also explained in terms of differences in sex ster-
oids secretion during pubertal development. Previous 
studies have revealed testosterone levels in boys [29] 
and oestrogen concentration in girls [30] to be the best 
predictors of bone markers.
There are several potential limitations of this study. 
Firstly, we measured only total osteocalcin concen-
tration. Both forms of osteocalcin, carboxylated and 
under-carboxylated, are secreted by osteoblasts and 
released into circulation. Uncarboxylated osteocalcin is 
biologically active in mice, but the clinical significance 
of these two forms in humans is not fully explained. 
For instance, in one study in older men and women, 
serum uncarboxylated osteocalcin was not associated 
with insulin resistance [31] whereas Schafer et al. [32] 
confirmed the association between undercarboxylated 
OC and metabolic parameters.
Another limitation of our study was that we used 
only waist circumference as a surrogate of abdominal 
obesity. Although magnetic resonance or computed 
tomography would have provided more precise in-
formation about visceral fat tissue, we recognise the 
limitations of using these methods in children. Another 
important limitation to note is the lack of correlation of 
serum osteocalcin with bone mineral density. Further 
prospective studies are needed to assess the impact of 
low osteocalcin level on growing bones.
We were unable to demonstrate the effect of physi-
cal exercise on serum OC levels. Our group included 
obese children and adolescents whose level of physical 
activity was generally low. Further studies are under 
way to determine the influence of physical training, as 
a part of obesity intervention programme, on serum 
osteocalcin levels in children.
Reciprocal relationships between osteocalcin and 
systemic energy metabolism have been recently ex-
plained by the hypothesis about common origin of 
the osteoblast with the other cells involved in glucose 
and fat metabolism (adipocytes and muscle cells) [28]. 
Moreover, adipose tissue, in vitro, is able to secrete osteo-
calcin in both uncarboxylated and carboxylated forms 
[29], therefore the contribution of bone and fat tissue to 
circulating osteocalcin should be further investigated.
Our study in obese children and adolescents pro-
vides further insight into the regulatory hormonal loop 
comprising adipose tissue, insulin, and osteocalcin by 
taking into account metabolic risk parameters. 
In conclusion, we demonstrate that serum osteocal-
cin levels are independently associated with parameters 
of the dysmetabolic phenotype, including insulin resist-
ance, triglycerides and abdominal obesity. The potential 
of osteocalcin as a medication for ameliorating the dys-
metabolic profile in at-risk individuals is speculative at 
present, but merits additional investigation.
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